Bayer Stivarga Program

Bayer Stivarga Program

Cancer-News

1 year
317 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Scott Fields, M.D., SVP Head Pharmaceutical Development Oncology at Bayer Pharmaceuticals discusses Bayer Stivarga Program. At ESMO Oncology Conference - Munich, Germany On October 19, 2018.
Up Next Autoplay
Loss of SETD2 is associated with dysregulation of protein translation in clear cell renal cell carcinoma
Loss of SETD2 is associated with dysregulation of protein translation in clear cell renal cell carcinoma
Category: Kidney Cancer
2 Views
kidneycancer 1 day
Immune Correlates and Prognostic Significance of CD73 Expression in Renal Cell Carcinoma
Immune Correlates and Prognostic Significance of CD73 Expression in Renal Cell Carcinoma
Category: Kidney Cancer
5 Views
kidneycancer 1 day
Using Epigenetic Therapy to Enhance Immunotherapy Response in RCC
Using Epigenetic Therapy to Enhance Immunotherapy Response in RCC
Category: Kidney Cancer
4 Views
kidneycancer 1 day
Radiation to Prime the Immune System
Radiation to Prime the Immune System
Category: Kidney Cancer
8 Views
kidneycancer 1 day
Therapeutic targeting of the extracellular matrix in kidney cancer
Therapeutic targeting of the extracellular matrix in kidney cancer
Category: Kidney Cancer
2 Views
kidneycancer 1 day
Innate Cytokines and Myeloid Cells
Innate Cytokines and Myeloid Cells
Category: Kidney Cancer
1 Views
kidneycancer 1 day
DNA Demethylation promotes ERV expression and activation of immune signaling in renal cell cancer cells
DNA Demethylation promotes ERV expression and activation of immune signaling in renal cell cancer cells
Category: Kidney Cancer
0 Views
kidneycancer 1 day
The T-cell response to Kidney Cancer
The T-cell response to Kidney Cancer
Category: Kidney Cancer
1 Views
kidneycancer 1 day
Discovery of new IO Targets Leveraging CRISPR
Discovery of new IO Targets Leveraging CRISPR
Category: Kidney Cancer
1 Views
kidneycancer 1 day
Patient-reported ECOG performance status (PS) is lower than oncologist-reported PS and is associated with worse psychosocial outcomes
Patient-reported ECOG performance status (PS) is lower than oncologist-reported PS and is associated with worse psychosocial outcomes
Category: Kidney Cancer
2 Views
kidneycancer 1 day